PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: 919 Marketing

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Gentris Corporation to Exclusively Market its FDA-Approved Human Genomic Reference Controls - NC-based pharmacogenomics company has achieved its first FDA product clearance just two years after launching diagnostics division - Gentris.com
Gentris Corporation to Exclusively Market its FDA-Approved Human Genomic Reference Controls

 

NewswireToday - /newswire/ - Holly Springs, NC, United States, 2007/01/24 - NC-based pharmacogenomics company has achieved its first FDA product clearance just two years after launching diagnostics division - Gentris.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Gentris Corporation (Gentris) today announced FDA clearance for GentriSure™, its first product line and the first FDA-cleared product for this specialty pharmacogenomics company. These six Human Genomic Reference Controls, the first products of their kind approved by a federal agency, are used to perform diagnostic testing for the Cytochrome P450 2D6 gene (CYP2D6). Gentris, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, can now add FDA approval and a GMP-compliant device manufacturer to its long list of accomplishments.

“The FDA’s approval of our GentriSure product line is an extremely important achievement for Gentris,” said Michael Murphy, the company’s President and CEO. “It demonstrates our ability to implement a GMP-compliant facility, as well as to navigate the regulatory process. This latest development also proves our capability to expediently manage the complexities of conducting clinical trials with our products.” he added. “We are already applying the same model to other products in our pipeline.”

FDA approval reflects the growing demand for consistent, reliable genomic material obtained from properly consented patients. Previously, the only other sources of available reference materials for CYP2D6 diagnostic testing were surplus human specimens and synthetics. All of these materials are generally less desirable due to consistency, ethical and representative issues.

“Gentris’ FDA-cleared human genomic reference controls for CYP2D6 set an important precedent in the pharmacogenomics arena,” commented William Evans, Pharm.D., Director and CEO, St. Jude Children’s Research Hospital in Memphis, Tennessee. “Controls are as important as tests in ensuring accurate and safe clinical testing. As one of the few FDA cleared pharmacogenomic-related diagnostics, each new Gentris product is a step closer to personalized drug treatment,” said Dr. Evans.

In compliance with strict FDA submission requirements, Gentris conducted user trials at three outside, independent sites to validate the efficacy and quality of these products. The sites included one of the world's largest clinical reference laboratories, a world-renowned reference laboratory for national and international clinics and hospitals, and an independent laboratory spun out of a university that specializes in clinical pharmacogenetic testing. GentriSure controls were tested on several CYP2D6 test platforms including laboratory developed assays. Notably, GentriSure Human Genomic Reference Controls were tested on the Roche AmpliChip®, CYP450 Test, the only FDA cleared device for CYP2D6 testing on the market.

About Gentris Corporation

Gentris Corporation (gentris.com) is a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions. As pioneers in the field of pharmacogenomics, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market sooner. Gentris is developing validated reference controls and diagnostic test kits that will bring the promise of personalized medicine to physicians and patients, which will enhance patient management, improve patients' response to therapy and revolutionize medicine through pharmacogenomics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: 919 Marketing

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Gentris Corporation to Exclusively Market its FDA-Approved Human Genomic Reference Controls

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Mariana McCulley - 919Marketing.com 
919-557-7890 mmcculley[.]919marketing.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any 919 Marketing securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From 919 Marketing / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)